Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | APLNR | P35414 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.57 |
| ▸ | BCHE | P06276 | 3/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9080543 | 0.89 | KDM4E (0.77) | KDM4EALDH1A1MEN1KMT2AHDAC3 | |
| SCHEMBL8883322 | 0.88 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ACHRM2 | |
| SCHEMBL5695121 | 0.86 | ALDH1A1 (0.79) | KDM4EALDH1A1MEN1KMT2ACHRM2 | |
| SCHEMBL21159301 | 0.83 | APLNR (0.83) | KDM4EALDH1A1MEN1KMT2AAPLNR | |
| SCHEMBL1279045 | 0.82 | HTT (0.73) | KDM4EALDH1A1MEN1KMT2ACHRM2 | |
| SCHEMBL121529 | 0.82 | CHRM2 (0.70) | KDM4EALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL8880359 | 0.81 | APLNR (0.78) | KDM4EALDH1A1MEN1KMT2AHDAC3 | |
| Hydrochloric Acid SCHEMBL9479560 | 0.80 | CHRM2 (0.68) | KDM4EALDH1A1HDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL2147064 | 0.80 | CHRM2 (0.68) | KDM4EALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL15131259 | 0.80 | MEN1 (0.76) | KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-4347590-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | KDM4E 3515/4885ALDH1A1 2000/4885MEN1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.